83 results on '"Canaani, Jonathan"'
Search Results
2. Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis
3. Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT
4. Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol
5. ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy
6. Evaluation of the clinical impact of bone marrow cultures in current medical practice
7. Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy
8. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
9. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
10. Impact of Cytogenetic Risk on Outcomes of Non-T-Cell–Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia
11. Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT
12. A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity
13. Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia
14. Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation
15. Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia.
16. Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients.
17. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation
18. Thiotepa‐based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched‐pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
19. Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies
20. Real-World Efficacy Outcomes of FLT3-ITD mut Acute Myeloid Leukemia Patients Treated with Midostaurin in Combination with Intensive Induction.
21. FGF-2 expands murine hematopoietic stem and progenitor cells via proliferation of stromal cells, c-Kit activation, and CXCL12 down-regulation
22. Predictive Parameters for a Diagnostic Bone Marrow Biopsy Specimen in the Work-Up of Fever of Unknown Origin
23. Contemporary evaluation of acute myeloid leukemia patients with long‐term survival exceeding 5 years.
24. Heparanase expression increases throughout the endometrial hyperplasia–cancer sequence
25. Acute myeloid leukemia with 11q23/MLL rearrangement after ‘FCR’ regimen for chronic lymphocytic leukemia
26. Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3‐ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation.
27. Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy.
28. T-Wave Amplitude Is Related to Physical Fitness Status
29. Complete Remission with Incomplete Blood Count Recovery Is a Strong Predictor of Nonrelapse Mortality in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.
30. Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease
31. Outcome of T‐cell–replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
32. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
33. A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia.
34. Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation
35. Two‐dimensional speckle‐tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia.
36. Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T‐cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
37. T‐cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3‐ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
38. ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.
39. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT.
40. Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT.
41. Established and emerging targeted therapies in the myelodysplastic syndromes.
42. Revisiting maintenance therapy in acute myeloid leukemia with novel agents.
43. Association of Preoperative Clinical, Laboratory, Imaging, and Pathologic Data With Clinically Beneficial Pathology Among Routine Splenectomy Specimens.
44. Paradoxical Immune Reconstitution Inflammatory Syndrome Associated With Rituximab-Containing Regimen in a Patient With Lymphoma.
45. Gilteritinib with or without venetoclax for relapsed/refractory FLT3‐mutated acute myeloid leukaemia.
46. Defining the Prognostic Implications of Recurring Cytogenetic Aberrations and FLT3-ITD in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation: On Behalf of the ALWP of the EBMT.
47. 98 - Minimal Residual Disease Status in Acute Myeloid Leukemia Patients Undergoing T-Cell Replete Haploidentical Transplantation. an Analysis From the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (Ebmt).
48. Acute myeloid leukemia with 11q23/ MLL rearrangement after ' FCR' regimen for chronic lymphocytic leukemia.
49. Use of FLT3 Inhibitors to Bridge Relapsed/Refractory AML Patients to an Allogeneic Stem Cell Transplant.
50. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.